Strategic partnerships Chiesi USA is actively expanding through collaborations and alliances, such as the recent partnership with Arbor Biotechnologies and the Karolinska Institutet collaboration, signaling growth opportunities in gene editing, rare diseases, and joint R&D initiatives that can open doors for co-development or co-commercialization with hospital and specialty channels.

Rare disease focus With a specialty portfolio targeting hospital and rare disease settings and ongoing initiatives in rare kidney conditions and other specialty care indications, there is a sales opportunity to expand access in institutional accounts and payor-accelerated pathways for high-need, low-volume therapies.

Innovation platform The launch of The Impulse innovation platform indicates a strategic push to accelerate partnerships and patient-centric solutions, presenting a doorway for business development to propose joint ventures, pilot programs, and strategic initiatives with health systems and biotech partners.

COPD and respiratory expansion Recent COPD-related product introductions and listing on national reimbursement lists create upsell and access opportunities in hospital and office-based settings, including formulary placement discussions, payer negotiations, and field sales engagements focused on adherence and patient outcomes.

Sustainability and citizenship As a public benefit corporation with a commitment to good corporate citizenship and environmental standards (ISO 14001), there is a channel to emphasize sustainability-oriented product sourcing, packaging innovations (e.g., carbon capture packaging partnerships), and value-based selling to health systems prioritizing ESG criteria.